- Parties: The plaintiffs were Novartis Pharmaceuticals Canada Inc. and Novartis AG. The defendant was Apotex Inc.

- Subject Matter: This is a patent infringement action before the Federal Court under the Patented Medicines (Notice of Compliance) Regulations, in which Novartis seeks a declaration that Apotex's proposed generic trametinib tablets (0.5 mg and 2 mg), filed under an Abbreviated New Drug Submission comparing the product to MEKINIST, would infringe or induce infringement of Canadian Patent Nos. 2,775,803 and 2,882,437. Novartis also seeks a permanent injunction, delivery up or destruction of infringing products, and costs on the highest scale under section 6.12 of the Regulations. The case is ongoing.

- Date: A hearing was set on May 21, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.